绝经后骨质疏松患者对双膦酸盐治疗反应的药物遗传学:一项前瞻性研究。

Q2 Medicine
Journal of Bone Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI:10.11005/jbm.24.787
Sirin Akbulut Ayturk, Ozden Ozyemisci Taskiran, Ebru Koseoglu Tohma, Aylin Sepici Dincel, Nesrin Demirsoy, Vesile Sepici
{"title":"绝经后骨质疏松患者对双膦酸盐治疗反应的药物遗传学:一项前瞻性研究。","authors":"Sirin Akbulut Ayturk, Ozden Ozyemisci Taskiran, Ebru Koseoglu Tohma, Aylin Sepici Dincel, Nesrin Demirsoy, Vesile Sepici","doi":"10.11005/jbm.24.787","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the effect of genetic polymorphisms of vitamin D receptor (VDR), estrogen receptor 1 (ER1), and Col1a1 on the response to bisphosphonate (BP) therapy in women with postmenopausal osteoporosis (OP).</p><p><strong>Methods: </strong>Twenty-one women with postmenopausal OP who received alendronate, ibandronate, or zoledronic acid for one year were enrolled in this study. Bone mineral density (BMD) at the lumbar spine and femoral neck were assessed by dual energy X-ray absorptiometry at baseline and after 12 months. Serum osteocalcin levels were measured at baseline and after 12 months. Polymorphic sites of the genes encoding ER1, VDR and Col1a1 proteins were amplified by polymerase chain reaction and examined using restriction fragment length polymorphism. Response to BP treatment and change in osteocalcin levels were compared among women with different gene polymorphisms.</p><p><strong>Results: </strong>Ratio of responders to treatment regarding improvements in the BMD of lumbar spine and femoral neck was adequate in 76% and 62%, respectively. There was no significant difference in treatment response regarding BMD in either region or change in serum osteocalcin levels among different gene polymorphisms.</p><p><strong>Conclusions: </strong>These findings did not support the potential role of VDR BsmI, Col1a1 Sp1, ER1 PvuII, or XbaI polymorphisms in predicting the response to BP therapy in women with postmenopausal OP. Further investigation with larger prospective studies is required.</p>","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 1","pages":"21-30"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960302/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study.\",\"authors\":\"Sirin Akbulut Ayturk, Ozden Ozyemisci Taskiran, Ebru Koseoglu Tohma, Aylin Sepici Dincel, Nesrin Demirsoy, Vesile Sepici\",\"doi\":\"10.11005/jbm.24.787\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aims to investigate the effect of genetic polymorphisms of vitamin D receptor (VDR), estrogen receptor 1 (ER1), and Col1a1 on the response to bisphosphonate (BP) therapy in women with postmenopausal osteoporosis (OP).</p><p><strong>Methods: </strong>Twenty-one women with postmenopausal OP who received alendronate, ibandronate, or zoledronic acid for one year were enrolled in this study. Bone mineral density (BMD) at the lumbar spine and femoral neck were assessed by dual energy X-ray absorptiometry at baseline and after 12 months. Serum osteocalcin levels were measured at baseline and after 12 months. Polymorphic sites of the genes encoding ER1, VDR and Col1a1 proteins were amplified by polymerase chain reaction and examined using restriction fragment length polymorphism. Response to BP treatment and change in osteocalcin levels were compared among women with different gene polymorphisms.</p><p><strong>Results: </strong>Ratio of responders to treatment regarding improvements in the BMD of lumbar spine and femoral neck was adequate in 76% and 62%, respectively. There was no significant difference in treatment response regarding BMD in either region or change in serum osteocalcin levels among different gene polymorphisms.</p><p><strong>Conclusions: </strong>These findings did not support the potential role of VDR BsmI, Col1a1 Sp1, ER1 PvuII, or XbaI polymorphisms in predicting the response to BP therapy in women with postmenopausal OP. Further investigation with larger prospective studies is required.</p>\",\"PeriodicalId\":15070,\"journal\":{\"name\":\"Journal of Bone Metabolism\",\"volume\":\"32 1\",\"pages\":\"21-30\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960302/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11005/jbm.24.787\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11005/jbm.24.787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:本研究旨在探讨维生素D受体(VDR)、雌激素受体1 (ER1)和Col1a1基因多态性对绝经后骨质疏松症(OP)患者双膦酸盐(BP)治疗效果的影响。方法:21名接受阿仑膦酸、依班膦酸或唑来膦酸治疗一年的绝经后OP妇女参加了这项研究。基线和12个月后,采用双能x线骨密度仪评估腰椎和股骨颈的骨密度(BMD)。在基线和12个月后测定血清骨钙素水平。利用聚合酶链反应扩增ER1、VDR和Col1a1蛋白编码基因的多态性位点,并采用限制性内切片段长度多态性检测。比较不同基因多态性的女性对BP治疗的反应和骨钙素水平的变化。结果:治疗对腰椎和股骨颈骨密度改善的反应率分别为76%和62%。不同基因多态性的患者在骨密度和血清骨钙素水平方面的治疗效果无显著差异。结论:这些发现不支持VDR BsmI、Col1a1 Sp1、ER1 pvii或XbaI多态性在预测绝经后op妇女对BP治疗的反应中的潜在作用。需要进一步进行更大规模的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study.

Background: This study aims to investigate the effect of genetic polymorphisms of vitamin D receptor (VDR), estrogen receptor 1 (ER1), and Col1a1 on the response to bisphosphonate (BP) therapy in women with postmenopausal osteoporosis (OP).

Methods: Twenty-one women with postmenopausal OP who received alendronate, ibandronate, or zoledronic acid for one year were enrolled in this study. Bone mineral density (BMD) at the lumbar spine and femoral neck were assessed by dual energy X-ray absorptiometry at baseline and after 12 months. Serum osteocalcin levels were measured at baseline and after 12 months. Polymorphic sites of the genes encoding ER1, VDR and Col1a1 proteins were amplified by polymerase chain reaction and examined using restriction fragment length polymorphism. Response to BP treatment and change in osteocalcin levels were compared among women with different gene polymorphisms.

Results: Ratio of responders to treatment regarding improvements in the BMD of lumbar spine and femoral neck was adequate in 76% and 62%, respectively. There was no significant difference in treatment response regarding BMD in either region or change in serum osteocalcin levels among different gene polymorphisms.

Conclusions: These findings did not support the potential role of VDR BsmI, Col1a1 Sp1, ER1 PvuII, or XbaI polymorphisms in predicting the response to BP therapy in women with postmenopausal OP. Further investigation with larger prospective studies is required.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Bone Metabolism
Journal of Bone Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.70
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信